Lymphoma & Plasma Cell Disorders
Feature
Outpatient CAR T: Safe, Effective, Accessible
'The future of CAR T-cell therapy lies in balancing safety with accessibility,' says expert.
Feature
Cannabis in Cancer: What Oncologists and Patients Should Know
Access to and use of cannabis alongside cancer care have outpaced the science on evidence-based indications, according to an ASCO expert panel.
From the Journals
Risk Assessment Tool Can Help Predict Fractures in Cancer
Researchers collected data on bone mineral density and fractures in 9,877 patients with cancer and 45,875 matched control individuals without...
Latest News
New Scanner Creates Highly Detailed, 3D Images of Blood Vessels in Seconds
Researchers created a scanner that provides 3D images of vasculature, useful in RA, PVD, and cancer treatment.
Feature
Popular Weight Loss Drugs Now for Patients With Cancer?
Research suggests that obesity can reduce the effectiveness of cancer therapies.
From the Journals
Does Medicare Advantage Offer Higher-Value Chemotherapy?
Researchers conducted a cohort study to look at Medicare Advantage enrollment and treatment patterns for patients with cancer receiving...
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
Feature
Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?
Researchers analyzed whole genome sequencing data from 10,866 women in the WHI to explore possible associations between CHIP, mCA, and solid...
Feature
Prediction, Management of Sjögren-Related Lymphomas Gain Ground With New Studies
Two European studies reported on a potentially strong predictive biomarker for marginal lymphoma in Sjögren disease and the effectiveness of...
From the Journals
Teclistamab Promising as a Treatment of Last Resort for Refractory Autoimmune Diseases
In small studies, teclistamab significantly improved autoimmune disease activity and demonstrated a good safety profile.